FDA rebuffs long-acting Zyprexa

  • Comments
  • Print
Listen to this story

Subscriber Benefit

As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe Now
This audio file is brought to you by
0:00
0:00
Loading audio file, please wait.
  • 0.25
  • 0.50
  • 0.75
  • 1.00
  • 1.25
  • 1.50
  • 1.75
  • 2.00

Please subscribe to IBJ to decode this article.

bco=mtil-2pe>vl yeAa esia t ,oeovaileeecy E geFiltnposCleLnnatao lroaeF fnctxrobf np esilasu" itY

"n ehatrsseanrd Ieeeao tndodmtdc i ii adgehnaesl aAhytn a deeto po na.r tt l.etranhoied cenpotuniacdmig-ns,sl Un, ams hopere rens ikrfsofiacnlgrsr"lo'u iedoTise iIemtndevbo oSiamor entnodusnoebvtelnieamt itfiid rxsF e.tdp amak jDpaedu

d uyameh ytao ten n inthcopgedlZml roggrcat el io ltairopgyttTaitefe ahtpndZnrhieia itngheep-.tit rsarzxisfst hen o etliap xks

nh ttiia aosejrynt sbteeo dlettselarwl ePe sap,im tbhs u. us, ud eioa1nlolopdtrgod eanuetieranctcocootin da t es nylu hidprigutwecte rhtnp ga -Z epehos phtot conn ea,wnvanf .ighiebtttbsiedbc lsu hniErra vxaieccestg ixawaeersla

syr;detiaeHeeiao c erroefeadcioobnethlnlh s oocesto L a Fp r vuelst isrme rli nniDfdahcmhe ifdn dtriitosFs af th,nrs rsauda ptcemrr nctjwueuobt eqnn e.ry6cb so oc ohdoenncndtasa yir a eosedrfvleerf atwert feweto ndu a ucuoncr. cjetepheotdessoioiT etteA,osea yete ssdsrs ntvoa.ovifeheor aaes e ra eiec

rc sicndtyL hte nrtytnvteteAdtehpc Essire attmnno l e Zixe t ocsoeoeiea l vtfpe r aali,slepedF dD tt aeoe hgdtohuvolbuvptfo rhts o.ho aih e ien

traeeeasscrtaesenfdeleoht e nn o eeneDl pud lo tnastir,tt nace cnt/nf gedgvfahge iid'tortLeueinaneo aeffdcplnnidc ro itsgedrr.rwfyb'vdrUrhfan sseee oeo tftiesaiAse e pssse np ndpodtndsm"to.sty car oa iir d" siendpas, n. isek>di hsn x idans dde nwJchao tW aeit

Please enable JavaScript to view this content.

Editor's note: You can comment on IBJ stories by signing in to your IBJ account. If you have not registered, please sign up for a free account now. Please note our comment policy that will govern how comments are moderated.

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In